Resonant, a subsidiary of Renew Biotechnologies, has unveiled groundbreaking research focused on advancing neurodegenerative disease diagnostics. The recent publication introduces a novel blood biomarker for neurodegeneration, demonstrating an impressive 100% accuracy in identifying both Alzheimer's disease patients and individuals with Mild Cognitive Impairment (MCI), a precursor to Alzheimer's. Given the prevalence of Alzheimer's affecting approximately 6.7 million Americans aged 65 and older, with projections indicating a rise to 14 million by 2060, the need for early and accurate diagnosis is crucial, although challenging.

While the hallmark of Alzheimer's is neuron death, existing neurodegeneration biomarkers have faced limitations due to their lack of specificity. Resonant's assay addresses this issue by analyzing neuron type-specific DNA present in the blood. The company is actively working towards ensuring widespread accessibility for its test, supporting comprehensive treatment strategies for various neurodegenerative diseases. Resonant aims to make the diagnostic tool available for clinical screening, research purposes, and direct consumer access. To enhance the assay's cell-specificity and predictive accuracy, researchers are currently refining their methods using proprietary DNA sequencing technology provided by Wasatch Biolabs (WBL), Resonant's clinical laboratory service provider.

In addition to Alzheimer's, Resonant plans to extend the application of this technology to other neurodegenerative conditions characterized by cell-specific pathologies, such as Parkinson's Disease and Amyotrophic Lateral Sclerosis (ALS). The company is committed to creating innovative testing solutions for early detection, empowering clinicians, researchers, and individuals in the effective diagnosis, treatment, and management of neurodegenerative diseases. The anticipated launch date for the Alzheimer's test is in the first quarter of 2024.

Source: prnewswire.com